Back to top
more

Array Technologies (ARRY)

(Delayed Data from NSDQ)

$13.56 USD

13.56
3,494,190

-0.26 (-1.88%)

Updated Jun 4, 2024 04:00 PM ET

After-Market: $13.57 +0.01 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 12% (218 out of 249)

Industry: Solar

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ARRY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

[ARRY]

Reports for Purchase

Showing records 521 - 540 ( 545 total )

Industry: Medical - Biomedical and Genetics

Record: 521

06/07/2019

Company Report

Pages: 8

Price: 24.95

Industry: Medical - Biomedical and Genetics

Record: 522

05/10/2019

Company Report

Pages: 9

Price: 24.95

Industry: Medical - Biomedical and Genetics

Record: 523

04/30/2019

Company Report

Pages: 9

Price: 24.95

Industry: Medical - Biomedical and Genetics

Record: 524

03/27/2019

Company Report

Pages: 7

Price: 24.95

Industry: Medical - Biomedical and Genetics

Record: 525

09/09/2012

Industry Report

Pages: 5

Biotechnology Balance Sheet.

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 526

09/01/2012

Industry Report

Pages: 5

BIOTECHNOLOGY BALANCE SHEET - August 31st, 2012

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 527

03/29/2012

Industry Report

Pages: 3

2012 AACR Planner, Check. Next Stop, Chicago

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 528

11/08/2011

Industry Report

Pages: 3

Life Sciences -2011 ASH PLANNER

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 529

03/30/2011

Company Report

Pages: 3

We are placing Array BioPharma Under Review due to the departure from the firm of analyst, Simos Simeonidis

Provider: RODMAN & RENSHAW, CO.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 530

03/30/2011

Company Report

Pages: 3

We are placing Array BioPharma Under Review due to the departure from the firm of analyst, Simos Simeonidis

Provider: RODMAN & RENSHAW, CO.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 531

02/02/2011

Daily Note

Pages: 5

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 532

02/01/2011

Company Report

Pages: 7

Reports 2Q11 numbers; waiting for selumetinib (MEK inhibitor) data this year

Provider: RODMAN & RENSHAW, CO.

Analyst: SIMEONIDIS S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 533

02/01/2011

Daily Note

Pages: 3

Reports 2Q11 numbers; waiting for selumetinib (MEK inhibitor) data this year

Provider: RODMAN & RENSHAW, CO.

Analyst: SIMEONIDIS S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 534

12/10/2010

Industry Report

Pages: 3

Week in Review: Oncology and Stem Cell Sectors

Provider: RODMAN & RENSHAW, CO.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 535

12/06/2010

Company Report

Pages: 3

KSP inhibitor looks good in heavily pretreated Multiple Myeloma patients

Provider: RODMAN & RENSHAW, CO.

Analyst: SIMEONIDIS S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 536

11/10/2010

Daily Note

Pages: 14

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 537

11/09/2010

Company Report

Pages: 3

Reports 1Q11; keeping spending in check, while advancing internal pipeline

Provider: RODMAN & RENSHAW, CO.

Analyst: SIMEONIDIS S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 538

10/04/2010

Industry Report

Pages: 3

R&R?s Week in Review: Oncology and Stem Cell Sectors

Provider: RODMAN & RENSHAW, CO.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 539

08/12/2010

Company Report

Pages: 3

13 clinical compounds at a $157M market cap: should interest investors with long-term horizon

Provider: RODMAN & RENSHAW, CO.

Analyst: SIMEONIDIS S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 540

08/12/2010

Daily Note

Pages: 10

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party